OptiNose Inc (OPTN)
1.16
0.00 (0.00%)
USD |
NASDAQ |
May 22, 16:00
1.16
0.00 (0.00%)
After-Hours: 20:00
OptiNose SG&A Expense (Quarterly): 20.52M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 20.52M |
December 31, 2023 | 18.96M |
September 30, 2023 | 18.01M |
June 30, 2023 | 20.10M |
March 31, 2023 | 22.72M |
December 31, 2022 | 23.31M |
September 30, 2022 | 25.49M |
June 30, 2022 | 29.51M |
March 31, 2022 | 29.34M |
December 31, 2021 | 26.34M |
September 30, 2021 | 25.80M |
June 30, 2021 | 27.31M |
March 31, 2021 | 27.18M |
December 31, 2020 | 28.11M |
September 30, 2020 | 24.58M |
June 30, 2020 | 25.70M |
Date | Value |
---|---|
March 31, 2020 | 27.06M |
December 31, 2019 | 26.54M |
September 30, 2019 | 25.27M |
June 30, 2019 | 26.00M |
March 31, 2019 | 26.34M |
December 31, 2018 | 23.66M |
September 30, 2018 | 22.09M |
June 30, 2018 | 21.86M |
March 31, 2018 | 28.01M |
December 31, 2017 | 18.48M |
September 30, 2017 | 6.553M |
June 30, 2017 | 3.588M |
March 31, 2017 | 3.073M |
December 31, 2016 | 1.812M |
September 30, 2016 | 1.761M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
18.01M
Minimum
Sep 2023
29.51M
Maximum
Jun 2022
24.89M
Average
25.75M
Median
SG&A Expense (Quarterly) Benchmarks
Madrigal Pharmaceuticals Inc | 80.80M |
Viking Therapeutics Inc | 9.97M |
Zevra Therapeutics Inc | 9.931M |
CytomX Therapeutics Inc | 7.754M |
Spero Therapeutics Inc | 5.917M |